Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study.
Riess JW, Lara MS, Lopez de Rodas M, Luxardi G, Herbert S, Shimoda M, Kelly K, Meerlev A, Moore E, Beckett L, Monjazeb A, Schalper K, Maverakis E, Gandara DR.
Riess JW, et al. Among authors: kelly k.
JTO Clin Res Rep. 2024 Jul 14;5(10):100706. doi: 10.1016/j.jtocrr.2024.100706. eCollection 2024 Oct.
JTO Clin Res Rep. 2024.
PMID: 39318388
Free PMC article.